Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) EBITDA: 2020-2025

Historic EBITDA for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to -$52.7 million.

  • Rhythm Pharmaceuticals' EBITDA fell 19.98% to -$52.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$186.2 million, marking a year-over-year increase of 29.87%. This contributed to the annual value of -$265.5 million for FY2024, which is 44.02% down from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported EBITDA of -$52.7 million as of Q3 2025, which was down 16.24% from -$45.3 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' EBITDA registered a high of -$34.4 million during Q1 2021, and its lowest value of -$139.9 million during Q1 2024.
  • For the 3-year period, Rhythm Pharmaceuticals' EBITDA averaged around -$54.1 million, with its median value being -$45.3 million (2025).
  • Its EBITDA has fluctuated over the past 5 years, first slumped by 166.29% in 2024, then soared by 66.40% in 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' EBITDA (Quarterly) stood at -$51.0 million in 2021, then rose by 17.43% to -$42.1 million in 2022, then rose by 1.99% to -$41.3 million in 2023, then grew by 0.02% to -$41.3 million in 2024, then declined by 19.98% to -$52.7 million in 2025.
  • Its last three reported values are -$52.7 million in Q3 2025, -$45.3 million for Q2 2025, and -$47.0 million during Q1 2025.